Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label, Multinational Study Of The Efficacy And Safety Of Ex Vivo, Lentiviral Vector-Mediated Gene Therapy AVR-RD-01 For Treatment-Naive Subjects With Classic Fabry Disease

Trial Profile

An Open-Label, Multinational Study Of The Efficacy And Safety Of Ex Vivo, Lentiviral Vector-Mediated Gene Therapy AVR-RD-01 For Treatment-Naive Subjects With Classic Fabry Disease

Recruiting
Phase of Trial: Phase II

Latest Information Update: 13 Nov 2018

At a glance

  • Drugs AVR RD 01 (Primary)
  • Indications Fabry's disease
  • Focus Adverse reactions
  • Sponsors AVROBIO
  • Most Recent Events

    • 13 Nov 2018 According to a AVROBIO media release, the Company plans to provide further updates in the first quarter of 2019
    • 01 Oct 2018 According to a AVROBIO media release, Enrollment continues in Phase 2 clinical trial and first patients 3-month results demonstrate AGA enzyme activity from AVR-RD-01 gene therapy in ERT-naive patient.
    • 09 Aug 2018 According to a AVROBIO media release, the company has recently held a pre-IND meeting and is planning open a U.S. site for this study in 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top